DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2019 của Sol-Gel Technologies Ltd.

Sol-Gel is a clinical-stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. Their lead product candidates, VERED for the treatment of papulopustular rosacea and TWIN and SIRS-T for the treatment of acne vulgaris (“acne”) are based upon their proprietary microencapsulation delivery system. This technology consists of microcapsules made of silica. Based on their pre-clinical and clinical data, this delivery system should enable them to develop and commercialize dermatological drug products that are more effective and/or have fewer side effects than currently marketed drugs.

TÊN CÔNG TY / COMPANY
Sol-Gel Technologies Ltd.

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
NASDAQ (US)

MÃ CHỨNG KHOÁN / TICKER
SLGL

KỲ BÁO CÁO
2019

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare